Key result
TXNIP/PDK4 inhibition with verapamil and dichloroacetic acid significantly reduced myocardial infarct size, decreased apoptosis, and improved cardiac function in diabetic mice following ischemia-reperfusion injury.
Why the study?
The specific mechanisms underlying increased myocardial vulnerability to ischemia-reperfusion injury in diabetic patients remain unknown.
Does inhibition of TXNIP and PDK4 with verapamil and dichloroacetic acid reduce myocardial vulnerability to ischemia-reperfusion injury in a diabetic mouse model?
Does inhibition of TXNIP and PDK4 with verapamil and dichloroacetic acid reduce myocardial vulnerability to ischemia-reperfusion injury in a diabetic mouse model?
Inhibiting TXNIP and PDK4 with verapamil and dichloroacetic acid reduces myocardial vulnerability to ischemia-reperfusion injury in diabetic mice by optimizing energy metabolism and reducing apoptosis.
No takes yet. Share an insight, caveat, or question.
Identifies a potential metabolic target for cardioprotection in diabetes; leaves open whether TXNIP.
Background Undergoing perioperative ischemia‐reperfusion injury (I/RI), the prevalence of adverse cardiac events is high due to increased myocardial vulnerability in diabetic patients. However, the specific mechanisms of increased myocardial vulnerability in diabetes are still unknown. Objective To investigate the specific mechanisms underlying increased myocardial vulnerability in diabetes and to explore potential myocardial protective strategies. Methods In this study, we repeatedly verified through single‐cell sequencing, fluorescence in situ staining, metabonomics, and animal experiments. Results Here we show for the first time that the cardiomyocyte subtype (C6 cardiomyocyte) is a cardiomyocyte characterized by myocardial contraction, and the reduction of its number and metabolic heterogeneity is the basis of myocardial ischemia‐reperfusion injury in diabetes. Among them, TXNIP/PDK4 mediated metabolic reprogramming is an important reason for myocardial vulnerability in diabetes, and through regulating TXNIP/PDK4, we optimize myocardial energy metabolism. It can significantly improve the vulnerability of diabetes myocardium, play a good role in myocardial protection, and has clinical transformation potential.
Zeng et al. (2026) studied Diabetic myocardial ischemia-reperfusion injury. TXNIP/PDK4 inhibitors (Verapamil and Dichloroacetic acid) vs. Untreated mice with ischemia-reperfusion injury was evaluated on Myocardial infarct size, apoptosis, and cardiac function (ejection fraction and fractional shortening) (p=<0.05). TXNIP/PDK4 inhibition with verapamil and dichloroacetic acid significantly reduced myocardial infarct size, decreased apoptosis, and improved cardiac function in diabetic mice following ischemia-reperfusion injury.